Gemtuzumab-ozogamicin (GO), an anti-CD33 antibody conjugated with calicheamicin, is the first antibody-based therapy approved for the treatment of AML in combination with induction chemotherapy. This evidence concerns the gene CD33 and acute myeloid leukemia.